Loading…
Cipla is a global pharmaceutical company focused on developing, manufacturing, and marketing a wide range of branded and generic formulations, Active Pharmaceutical Ingredients (APIs), with core strengths in respiratory, anti-retroviral, urology, cardiology, anti-infective, and CNS therapies. Strategic focus includes innovation, complex generics, biosimilars, and expanding global reach.
Extensive operations across India, including multiple manufacturing units, R&D centers, and strong market penetration in prescription, generics, and consumer health segments.
Focus on expanding presence in Tier 2-6 cities for Trade Generics, diversifying the portfolio with innovative products, entering the obesity management market with Semaglutide.
Significant presence in North America, South Africa, Europe, and various Emerging Markets, with 46 manufacturing sites globally catering to 78 markets.
Targeting launches of gSymbicort and gQvar in the US, launching four peptide assets in FY 2024-25, filing two significant respiratory assets in the next 12-15 months, introducing Spirofy device in multiple countries (Sri Lanka, Myanmar, Malaysia, Oman, Sub-Saharan Africa), co-developing mRNA assets with Ethris GmbH for India and LMICs, taking Stempeutics technology to regulated markets.
Regulatory approvals (USFDA, EMA, etc.), Government pricing policies (DPCO, NLEM, IRA), Market demand for pharmaceuticals, Input material costs and availability, Foreign exchange rates.
Strong R&D pipeline focusing on complex generics and inhalation therapies, Extensive global manufacturing and distribution network, Established leadership in key markets (India, South Africa), 'Caring for Life' brand equity and focus on accessibility, Cost-effective operations.
14:47 23 May 25
Detailed financial analysis and charts are coming soon!